Tirzepatide vs semaglutide: what the molecule difference means
Give a reader who has seen comparison headlines the molecule-level substance behind the Zepbound vs Wegovy debate, anchored in trial evidence rather than brand messaging.
Read moreThe Patient Intelligence Desk for GLP-1 News, Research, and Access
How GLP-1 and GIP Therapies Actually Work
A scene-by-scene explanation of satiety signaling, slower gastric emptying, insulin response, and why patients describe the sudden quieting of food noise.
Open interactiveCurrent headlines
Form Health vs Mochi Health comparison
A side-by-side look at Form Health and Mochi Health covering clinical structure, medications (including compounded vs. FDA-approved GLP-1s), cost, and insurance so you can decide which program fits your situation.
Read moreWhy Insurers Are Dropping or Changing GLP-1 Coverage in 2026
A plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreMost popular
What “Food Noise” Means and Why GLP-1 Patients Keep Using That Phrase
Across GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisTirzepatide vs semaglutide: what the molecule difference means
Give a reader who has seen comparison headlines the molecule-level substance behind the Zepbound vs Wegovy debate, anchored in trial evidence rather than brand messaging.
Full analysisOutside Publications We Track for Obesity, Metabolic Health, and GLP-1 Care
We track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Rotating three
Medical journalism with occasional obesity crossover
Medicine Uncovered
Started publishing Oct 2024
Medicine Uncovered is broader medical journalism first and a GLP-1 source second. It is worth tracking when obesity treatment starts crossing into larger reporting questions around medicine, health systems, and public understanding. This is a better fit for readers who want occasional strong reporting than for people looking for a dedicated obesity beat.
Broad physician-creator lens with occasional GLP-1 overlap
Mental Health Movement
Started publishing Jan 2023
Jake Goodman’s publication is mostly about mental health and public-facing medicine, not obesity treatment. It still earns a place here because the GLP-1 pieces are accessible, widely shared, and written for readers who want straightforward answers instead of specialist jargon. Think of it as a general-audience crossover source, not a dedicated obesity desk.
Health-tech and care-model analysis
Massively Better Healthcare
Started publishing Sep 2020
Halle Tecco is especially good at explaining how obesity care gets built, sold, reimbursed, and scaled. If you want to understand telehealth GLP-1 companies, payer pressure, startup behavior, and the business logic behind the care models patients keep running into, this is one of the sharper reads in the category. It is less about day-to-day prescribing and more about the machinery around modern obesity treatment.
What Patients Ask First
Managing Side Effects
Cost + Access
Precision Coverage
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.